Follistatin 344
Also known as: FS-344
Follistatin 344 is a recombinant form of the naturally-occurring glycoprotein (344-residue splice variant) that inhibits activin and myostatin signaling. Clinical validation exists ONLY through small AAV gene-therapy phase 1/2 trials in Becker muscular dystrophy; recombinant injectable protein sold on the grey market has no clinical evidence. NOT FDA-approved. WADA-prohibited (myostatin inhibitor) and banned in competitive sport.
Who's worth your money for Follistatin 344
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (88) of 1 scored sellers
$96.00 · 1mg
Average price
$126.55/mg
Sellers
9
45-day trend
-5.9%
7 of 9 sellers have a current price· 3 stale hidden· 3 unverified hidden
- 🇺🇸 Ruo Bio88
✓ verified at source · just now
$96.00/mg -24.1% vs avg$96.00
1mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch Follistatin 344
Get one email when the market actually moves — no newsletter, no noise.
About Follistatin 344
CAS
—
Molecular formula
—
Sequence
MVRARHQPGGLCLLLLLLCQFMEDRSAQAGNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW
Typical dose range
100–200 mcg/day subcutaneous (research use; cycles of 10–30 days on, 3–4 weeks off)
Half-life
~90 minutes (recombinant injectable form); endogenous FST-315 isoform estimated ~10–15 hours
COAs for Follistatin 344
2 third-party tests across 2 vendors. Each card links to the full report.
12 citations indexed for Follistatin 344
review · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.
Study · 2026
Grip strength as a systems biomarker of aging: neuromuscular junction constraints and biomarker decoupling in gene therapy
Grip strength has emerged as one of the most robust predictors of mortality, disability and healthspan across populations.
review · 2026
Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition
Liver cirrhosis is frequently complicated by sarcopenia, a progressive and systemic loss of skeletal muscle mass and function that contributes substantially to increased morbidity, mortality, and healthcare utilisation.
review · 2026
Disruption of the Muscle-Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration
This narrative review analyzes how myokines act as key links in communication between skeletal muscle and the brain, focusing on the impact of aging on this axis.
review · 2026
Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders
Myostatin (Mstn), a well-characterized member of the transforming growth factor-β (TGF-β) superfamily, serves as a key negative regulator of skeletal muscle mass. Its overactivation is closely associated with the pathogenesis of various musculoskeletal and metabolic disorders.